Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 360 entries
View as:

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02289950 Org: User:
Start: 03/19/15 End: 08/13/20 Due: 08/13/21

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02415790 Org: User:
Start: 07/31/15 End: 07/31/16 Due: 07/31/17

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Phase: N/A Priority: Normal
NCT ID: NCT04890561 Org: User:
Start: 05/17/21 End: 08/12/21 Due: 08/12/22

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

Phase: N/A Priority: Normal
NCT ID: NCT00368472 Org: User:
Start: 10/31/06 End: 07/31/14 Due: 07/31/15

A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

Phase: N/A Priority: Normal
NCT ID: NCT01276353 Org: User:
Start: 01/31/11 End: 04/30/12 Due: 04/30/13

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Phase: N/A Priority: Normal
NCT ID: NCT00839306 Org: User:
Start: 08/31/08 End: 01/31/10 Due: 01/31/11

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01327885 Org: User:
Start: 03/10/11 End: 08/10/16 Due: 08/10/17

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

Phase: N/A Priority: Normal
NCT ID: NCT01634360 Org: User:
Start: 11/30/04 End: 06/30/08 Due: 06/30/09

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

Phase: N/A Priority: Normal
NCT ID: NCT00230568 Org: User:
Start: 12/31/05 End: 12/31/07 Due: 12/31/08

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03376997 Org: User:
Start: 11/08/17 End: 02/16/18 Due: 02/16/19

Dose-Finding Study of E7070 in Combination With Irinotecan

Phase: N/A Priority: Normal
NCT ID: NCT00060567 Org: User:
Start: 03/31/03 End: 03/31/13 Due: 03/31/14

Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT02736162 Org: User:
Start: 04/30/16 End: 07/31/16 Due: 07/31/17

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01271504 Org: User:
Start: 07/19/11 End: 06/23/15 Due: 06/23/16

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Phase: N/A Priority: Normal
NCT ID: NCT00236184 Org: User:
Start: 10/31/05 End: 06/30/08 Due: 06/30/09

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02039089 Org: User:
Start: 01/31/14 End: 05/31/14 Due: 05/31/15

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Phase: N/A Priority: Normal
NCT ID: NCT05147337 Org: User:
Start: 12/01/21 End: 08/18/22 Due: 08/18/23

A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations

Phase: N/A Priority: Normal
NCT ID: NCT01127438 Org: User:
Start: 04/30/10 End: 06/30/11 Due: 06/30/12

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT04015141 Org: User:
Start: 05/31/19 End: 12/23/27 Due: 12/23/28

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00033735 Org: User:
Start: 01/31/00 End: - Due: -

A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.

Phase: N/A Priority: Normal
NCT ID: NCT01283256 Org: User:
Start: 01/31/11 End: 05/31/13 Due: 05/31/14

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05091346 Org: User:
Start: 10/27/21 End: 10/15/24 Due: 10/15/25

A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01209858 Org: User:
Start: 03/31/10 End: 10/31/10 Due: 10/31/11

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05533801 Org: User:
Start: 09/06/22 End: 01/06/23 Due: 01/06/24

An Extended Access Program for Perampanel

Phase: N/A Priority: Normal
NCT ID: NCT01871233 Org: User:
Start: - End: - Due: -

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Phase: N/A Priority: Normal
NCT ID: NCT03778424 Org: User:
Start: - End: - Due: -